Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.

ABSTRACT:

Unlabelled

Metastatic melanoma is a highly aggressive skin cancer with a poor prognosis. Despite a complete response in fewer than 5% of patients, the chemotherapeutic agent dacarbazine (DTIC) remains the reference drug after almost 40 years. More recently, FDA-approved drugs have shown promise but patient outcome remains modest, predominantly due to drug resistance. As such, combinatorial targeting has received increased attention, and will advance with the identification of new molecular targets. One attractive target for improving melanoma therapy is the growth factor Nodal, whose normal expression is largely restricted to embryonic development, but is reactivated in metastatic melanoma. In this study, we sought to determine how Nodal-positive human melanoma cells respond to DTI

SUBMITTER: Hardy KM 

PROVIDER: S-EPMC4398626 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature